v3.25.1
Earnings Per Share
6 Months Ended
Apr. 30, 2025
Earnings Per Share [Abstract]  
Earnings Per Share Earnings Per Share
We compute basic earnings per share by dividing net income by the weighted-average number of common shares outstanding during the period. Diluted earnings per common and potential common shares include the weighted-average of additional shares associated with the incremental effect of dilutive employee stock options, non-vested restricted stock as determined using the treasury stock method prescribed by U.S. GAAP and contingent shares associated with performance share awards, if dilutive.
Basic and diluted earnings per share for the three and six months ended April 30, 2025 and 2024 were calculated as follows (in thousands, except per share data):
Net (Loss) IncomeWeighted-Average SharesPer Share
Three Months Ended April 30, 2025
Basic earnings per common share$20,515 46,483 $0.44 
Effect of dilutive securities:
Stock options— — — 
Restricted stock awards— 60 — 
Performance restricted stock units— 20 — 
Diluted earnings per common share$20,515 46,563 $0.44 
Three Months Ended April 30, 2024
Basic earnings per common share$15,377 32,870 $0.47 
Effect of dilutive securities:
Stock options— 37 — 
Restricted stock awards— 130 — 
Performance restricted stock units— 66 — 
Diluted earnings per common share$15,377 33,103 $0.46 
Six Months Ended April 30, 2025
Basic and diluted loss per common share$5,630 46,753 $0.12 
Effect of dilutive securities:
Stock options— 11 — 
Restricted stock awards— 84 — 
Performance restricted stock units— 20 — 
Diluted earnings per common share$5,630 46,868 $0.12 
Six Months Ended April 30, 2024
Basic earnings per common share$21,626 32,847 $0.66 
Effect of dilutive securities:
Stock options— 37 — 
Restricted stock awards— 126 — 
Performance restricted stock units— 66 — 
Diluted earnings per common share$21,626 33,076 $0.65 
We do not include equity instruments in our calculation of diluted earnings per share if those instruments would be anti-dilutive. We had 41,871 and 17,580 of anti-dilutive restricted stock award equivalents for the three and six months ended April 30, 2025, respectively, and no corresponding equivalents for the comparable prior year periods. Such dilution is dependent on the excess of the market price of our stock over the exercise price and other components of the treasury stock method.